Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Gut–liver axis: barriers and functional circuits
Oliver Pabst, Mathias W. Hornef, Frank G. Schaap, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 7, pp. 447-461
Closed Access | Times Cited: 149

Showing 1-25 of 149 citing articles:

NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment Options
Natalia G. Vallianou, Dimitris Kounatidis, Sotiria Psallida, et al.
Metabolites (2024) Vol. 14, Iss. 7, pp. 366-366
Open Access | Times Cited: 18
Microfluidic-based multifunctional microspheres for enhanced oral co-delivery of probiotics and postbiotics
Xinyuan Yang, Weimin Nie, Chong Wang, et al.
Biomaterials (2024) Vol. 308, pp. 122564-122564
Closed Access | Times Cited: 16
Gut–liver translocation of pathogen Klebsiella pneumoniae promotes hepatocellular carcinoma in mice
Xueliang Wang, Yi Fang, Wei Liang, et al.
Nature Microbiology (2025)
Open Access | Times Cited: 4
Microbes Saving Lives and Reducing Suffering
Kenneth N. Timmis, Zeynep Ceren Karahan, Juan L. Ramos, et al.
Microbial Biotechnology (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 2
Gut Microbiota Secondary Metabolites: Key Roles in GI Tract Cancers and Infectious Diseases
Eman K. E. Anwer, Muhammad Ajagbe, Mohamed Sherif, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 100-100
Open Access | Times Cited: 1
The pathophysiology of MASLD: an immunometabolic perspective
Julian Schwärzler, Felix Grabherr, Christoph Grander, et al.
Expert Review of Clinical Immunology (2023) Vol. 20, Iss. 4, pp. 375-386
Closed Access | Times Cited: 25
Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis
Roman Maslennikov, Elena Poluektova, O. Yu. Zolnikova, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 22, pp. 16502-16502
Open Access | Times Cited: 24
Gut microbiota metabolite TMAO promoted lipid deposition and fibrosis process via KRT17 in fatty liver cells in vitro
Fulin Nian, Zhu Chen, Nuyun Jin, et al.
Biochemical and Biophysical Research Communications (2023) Vol. 669, pp. 134-142
Closed Access | Times Cited: 21
Amelioration of obesity and inflammation by polysaccharide from unripe fruits of raspberry via gut microbiota regulation
Yuzhe Huang, Jingjing Hu, Qijun Xia, et al.
International Journal of Biological Macromolecules (2024) Vol. 261, pp. 129825-129825
Closed Access | Times Cited: 13
Short-chain fatty acids in nonalcoholic fatty liver disease: New prospects for short-chain fatty acids as therapeutic targets
Xinyu Li, Maozhang He, Xinrui Yi, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e26991-e26991
Open Access | Times Cited: 12
The central role of the gut microbiota in the pathophysiology and management of type 2 diabetes
Daniel P Baars, Marcos F. Fondevila, Abraham S. Meijnikman, et al.
Cell Host & Microbe (2024) Vol. 32, Iss. 8, pp. 1280-1300
Closed Access | Times Cited: 11
Recent progress in Porphyra haitanensis polysaccharides: Extraction, purification, structural insights, and their impact on gastrointestinal health and oxidative stress management
Kit‐Leong Cheong, Keying Liu, Wenting Chen, et al.
Food Chemistry X (2024) Vol. 22, pp. 101414-101414
Open Access | Times Cited: 10
Endogenous ethanol production in health and disease
Abraham S. Meijnikman, Max Nieuwdorp, Bernd Schnabl
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 21, Iss. 8, pp. 556-571
Closed Access | Times Cited: 10
Probiotic Pediococcus pentosaceus restored gossypol-induced intestinal barrier injury by increasing propionate content in Nile tilapia
Feifei Ding, Nan-Nan Zhou, Yuan Luo, et al.
Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
Targeted delivery strategies: The interactions and applications of nanoparticles in liver diseases
Xiandi Meng, Ge Zhu, Yong‐Guang Yang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116702-116702
Open Access | Times Cited: 7
Hepatoprotective potential of four fruit extracts rich in different structural flavonoids against alcohol-induced liver injury via gut microbiota-liver axis
Yunyi Chen, Hanbing Ma, Jiaojiao Liang, et al.
Food Chemistry (2024) Vol. 460, pp. 140460-140460
Closed Access | Times Cited: 7
Polysaccharide from walnut green husk alleviates liver inflammation and gluconeogenesis dysfunction by altering gut microbiota in ochratoxin A-induced mice
Yang Yang, Linjie Lv, Shanshan Shi, et al.
Carbohydrate Polymers (2023) Vol. 322, pp. 121362-121362
Closed Access | Times Cited: 18
Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact
Anna Alisi, Geoffrey W. McCaughan, Henning Grønbæk
Hepatology International (2024) Vol. 18, Iss. S2, pp. 861-872
Closed Access | Times Cited: 7
Bacteria-based drug delivery for treating non-oncological diseases
Zhenping Cao, Yan Pang, Jun Pu, et al.
Journal of Controlled Release (2024) Vol. 366, pp. 668-683
Closed Access | Times Cited: 6
Polystyrene nanoplastics exacerbate aflatoxin B1-induced hepatic injuries by modulating the gut−liver axis
Kai-Kai Zhang, Jia-Yuan Wan, Yu‐Chuan Chen, et al.
The Science of The Total Environment (2024) Vol. 935, pp. 173285-173285
Closed Access | Times Cited: 5
Role of liver sinusoidal endothelial cell in metabolic dysfunction-associated fatty liver disease
Qiongyao He, Wu He, Hui Dong, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 5
The alleviative effects of viable and inactive Lactobacillus paracasei CCFM1120 against alcoholic liver disease via modulation of gut microbiota and the Nrf2/HO-1 and TLR4/MyD88/NF-κB pathways
Ben Niu, Yingxuan Feng, Cheng Xu, et al.
Food & Function (2024) Vol. 15, Iss. 17, pp. 8797-8809
Closed Access | Times Cited: 5
The role of gut microbiota in MP/NP-induced toxicity
Yinping Pan, Haojie Zhang, Liancai Zhu, et al.
Environmental Pollution (2024) Vol. 359, pp. 124742-124742
Closed Access | Times Cited: 5
Randomised double-blind placebo-controlled trial protocol to evaluate the therapeutic efficacy of lyophilised faecal microbiota capsules amended with next-generation beneficial bacteria in individuals with metabolic dysfunction-associated steatohepatitis
Quinten J. J. Augustijn, Aldo Grefhorst, Pleun de Groen, et al.
BMJ Open (2025) Vol. 15, Iss. 1, pp. e088290-e088290
Open Access
Exploring the effects of gut microbiota on cholangiocarcinoma progression by patient-derived organoids
Ann‐Kathrin Lederer, Nele Görrissen, Tinh Thi Nguyen, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top